Melanoma treatment patterns in japan: what Real-World data reveals

NCT ID NCT07649252

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines the patient profiles and treatment patterns of adults with melanoma in Japan who were prescribed either dabrafenib with trametinib or encorafenib with binimetinib. Researchers are looking at data from 2012 to 2021 to understand patient characteristics and how these targeted therapies are used in everyday practice. The goal is to gather real-world evidence that may inform future treatment approaches.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better understand how melanoma patients in Japan respond to targeted therapies, potentially improving treatment decisions.
What could go wrong: This is an observational study that does not test a new treatment, so it cannot prove what works best. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Novartis Pharma K.K.

Tokyo, 105-6333, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.